LAUSR

The aim of this study was to investigate the predictive value of the monocyte count as a prognostic biomarker on 90 days in patients with acute ischemic stroke (AIS) treated with recombinant tissue plasminogen activator (rtPA) thrombolysis. In total, 206 patients with AIS treated in our institute between 2013 and 2018 were retrospectively enrolled. All patients received rtPA thrombolytic therapy within 4.5 h of AIS onset. Using receiver operating characteristic (ROC) curve analysis, patients were divided into two groups according to monocyte count: a low monocyte count (LMC) group (monocytes < 0.53 × 10 9 /L) and a high monocyte count (HMC) group (monocytes ≥ 0.53 × 10 9 /L). Patients’ functional outcomes 90 days after AIS were assessed using the modified Rankin Scale. More patients had a poor outcome in the HMC group than in the LMC group (49.32% vs.31.58%, p  = 0.012). Multivariate logistic regression analysis revealed that infarct volume (odds ratio = 1.03, 95% confidence interval 1.01–1.04, p  < 0.001), systolic pressure at admission (odds ratio = 1.02, 95% confidence interval 1.00–1.04, p  = 0.016), fasting blood glucose at admission (odds ratio = 1.41, 95% confidence interval 1.18–1.67, p  < 0.001), and monocyte count ≥ 0.53 × 10 9 /L (odds ratio = 2.25, 95% confidence interval 1.09–4.62, p  = 0.028) were independently associated with a poor outcome in AIS patients treated with rtPA thrombolysis. A peripheral monocyte count ≥ 0.53 × 10 9 /L is an independent prognostic marker on 90-days in patients with AIS treated with rtPA thrombolysis.